(HCl), dopamine HCl, edetate calcium disodium, folic acid, glycopyrrolate, hydroxyzine HCl, ketorolac tromethamine, labetalol HCl, mannitol, metoclopramide HCl, moxifloxacin HCl, nalbuphine HCl, polidocanol, potassium acetate, procainamide HCl, sodium nitroprusside, sodium thiosulfate, and verapamil HCl. Interested persons were originally given until September 29, 2020, to comment on FDA’s proposals.

During the comment period for the July 31, 2020, notice, FDA received a request to allow interested persons additional time to comment. The requester asserted that the time period of 60 days was insufficient to respond fully to FDA’s specific requests for comments and noted the commenter’s obligations to respond to the exigencies of COVID–19 pandemic.

FDA has considered the request and other relevant factors, and accordingly is reopening the comment period for the July 31, 2020, notice for 30 days, until February 8, 2021. The Agency believes that an additional 30 days will allow adequate time for interested persons to submit comments.


Lauren K. Roth,  
Acting Principal Associate Commissioner for Policy.

[FR Doc. 2021–00123 Filed 1–7–21; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration  
[Docket No. FDA–2020–N–2300]

Determination That ARALEN (Chloroquine Phosphate) Oral Tablets, 500 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or Agency) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.

FOR FURTHER INFORMATION CONTACT: Stacy Kane, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6236, Silver Spring, MD 20993–0002; 301–796–8363, Stacy.Kane@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98–417) (the 1984 amendments), which authorized the approval of duplicate versions of drug products approved under an ANDA procedure. ANDA applicants must, with certain exceptions, show that the drug for which they are seeking approval contains the same active ingredient in the same strength and dosage form as the “listed drug,” which is a version of the drug that was previously approved. ANDA applicants do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA).

The 1984 amendments include what is now section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the “Approved Drug Products With Therapeutic Equivalence Evaluations,” which is known generally as the “Orange Book.” Under FDA regulations, a drug is removed from the list if the Agency withdraws or suspends approval of the drug’s NDA or ANDA for reasons of safety or effectiveness, or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162).

Under § 314.161(a) (21 CFR 314.161(a)), the Agency must determine whether a listed drug was withdrawn from sale for reasons of safety or effectiveness: (1) Before an ANDA that refers to that listed drug may be approved, (2) whenever a listed drug is voluntarily withdrawn from sale and ANDAs that refer to the listed drug have been approved, and (3) when a person petitions for such a determination under 21 CFR 10.25(a) and 10.30. Section 314.161(d) provides that if FDA determines that a listed drug was withdrawn from sale for safety or effectiveness reasons, the Agency will initiate proceedings that could result in the withdrawal of approval of the ANDAs that refer to the listed drug.

FDA has become aware that the drug products listed in the table are no longer being marketed.

<table>
<thead>
<tr>
<th>Application No.</th>
<th>Drug name</th>
<th>Active ingredient(s)</th>
<th>Strength(s)</th>
<th>Dosage form/route</th>
<th>Applicant</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA 006002</td>
<td>ARALEN .........</td>
<td>Chloroquine Phosphate</td>
<td>500 milligrams (mg)</td>
<td>Tablet; Oral</td>
<td>Sanofi-Aventis U.S. LLC.</td>
</tr>
<tr>
<td>NDA 006134</td>
<td>DOLOPHINE HYDROCHLORIDE.</td>
<td>Methadone Hydrochloride</td>
<td>5 mg; 10 mg</td>
<td>Tablet; Oral</td>
<td>Hikma Pharmaceuticals PLC.</td>
</tr>
<tr>
<td>NDA 007409</td>
<td>BENTYL ............</td>
<td>Dicyclomine Hydrochloride</td>
<td>10 mg</td>
<td>Capsule; Oral</td>
<td>Allergan Pharmaceuticals LLC.</td>
</tr>
<tr>
<td>NDA 008085</td>
<td>Methotrexate Sodium</td>
<td>Methotrexate Sodium</td>
<td>Equivalent to (EQ) 2.5 mg Base</td>
<td>Tablet; Oral</td>
<td>DAVA Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>NDA 008678</td>
<td>Isoniazid ..........</td>
<td>Isoniazid</td>
<td>100 mg; 300 mg</td>
<td>Tablet; Oral</td>
<td>Teva Branded Pharmaceutical Products.</td>
</tr>
<tr>
<td>NDA 012945</td>
<td>DIAMOX ..........</td>
<td>Acetazolamide</td>
<td>500 mg</td>
<td>Extended-Release Capsule; Oral</td>
<td>Eli Lilly and Co.</td>
</tr>
<tr>
<td>NDA 014103</td>
<td>ONCOVIN .........</td>
<td>Vincristine Sulfate</td>
<td>1 mg/mL; 1 mg/Vial; 5 mg/Vial</td>
<td>Injectable; Injection</td>
<td>Teva Women's Health, Inc.</td>
</tr>
<tr>
<td>NDA 016792</td>
<td>SURMONTIL ..........</td>
<td>Trimipramine Maleate</td>
<td>EQ 25 mg/Base; EQ 50 mg/ Base; EQ 100 mg/Base.</td>
<td>Capsule; Oral</td>
<td>Teva Women's Health, Inc.</td>
</tr>
</tbody>
</table>
FDA has reviewed its records and, under § 314.161, has determined that the drug products listed were not withdrawn from sale for reasons of safety or effectiveness. Accordingly, the Agency will continue to list the drug products in the “Discontinued Drug Product List” section of the Orange Book. The “Discontinued Drug Product List” identifies, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness.

Approved ANDAs that refer to the NDAs and ANDAs listed are unaffected by the discontinued marketing of the products subject to those NDAs and ANDAs. Additional ANDAs that refer to these products may also be approved by the Agency if they comply with relevant legal and regulatory requirements. If FDA determines that labeling for these drug products should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling.


Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Meeting of the National Advisory Committee on the National Health Service Corps

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: In accordance with the Federal Advisory Committee Act, this notice announces that the National Advisory Committee on the National Health Service Corps (NACNHSC) will hold public meetings for the 2021 calendar year (CY). Information about NACNHSC, agendas, and materials for these meetings can be found on the NACNHSC website at https://nhsc.hrsa.gov/about/national-advisory-council-nhsc/index.html.

DATES: NACNHSC meetings will be held on
- March 16, 2021, 9:00 a.m.–5:00 p.m. Eastern Time (ET) and March 17, 2021, 9:00 a.m.–2:00 p.m. ET;
- June 22, 2021, 9:00 a.m.–5:00 p.m. ET and June 23, 2021, 9:00 a.m.–2:00 p.m. ET;
- November 9, 2021, 9:00 a.m.–5:00 p.m. ET and November 10, 2021, 9:00 a.m.–2:00 p.m. ET.

ADDRESSES: Meetings may be held in-person, by teleconference, and/or Adobe Connect webinar. For updates on how the meeting will be held, visit the NACNHSC website 30 business days before the date of the meeting, where instructions for joining meetings either in-person or remotely will also be posted. In-person NACNHSC meetings will be held at 5600 Fishers Lane, Rockville, Maryland 20857. For meeting information updates, go to the NACNHSC website meeting page at https://nhsc.hrsa.gov/nac/meetings.html.

FOR FURTHER INFORMATION CONTACT: Diane Fabiyi-King (DFO), Division of National Health Service Corps, Bureau of Health Workforce, HRSA, 5600 Fishers Lane, Rockville, Maryland 20857; 301–443–3609; or NHSCAdvisoryCouncil@hrsa.gov.

SUPPLEMENTARY INFORMATION: NACNHSC provides advice and recommendations to the Secretary of HHS (Secretary) on policy, program development, and other matters of significance concerning the activities under Subpart II, Part D of Title III of the Public Health Service Act (42 U.S.C. 254d–254k). NACNHSC designates areas of the United States with health professional shortages and assigns National Health Service Corps clinicians to improve the delivery of health services in health professional shortage areas. Since priorities dictate meeting times and agenda items, be advised that start times, end times, and agenda items are subject to change. For CY 2021 meetings, agenda items may include, but are not limited to, the identification of NACNHSC priorities for future